Positive Two-Year Data from MiStent® DESSOLVE III Trial Presented at EuroPCR
- Excellent safety and low target lesion revascularization (TLR) rates persist -
DURHAM, North Carolina, May 23, 2018 /PRNewswire/ -- A 24-month update on the DESSOLVE III trial of the MiStent® Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent) was presented this week at EuroPCR 2018, an international congress of interventional cardiovascular medicine researchers and clinicians held in Paris, France.
Data were presented by William Wijns, M.D., Ph.D., of The Lambe Institute for Translational Medicine at the National University of Ireland and Co-Director of EuroPCR, in a late-breaking trial update session on drug-eluting stents (DES). Key points in the discussion included the continued lower rate of clinically-driven target lesion revascularization (CD-TLR) for the MiStent group compared to Xience, as well as a continued lower rate of definite stent thrombosis.
Additionally, this trial is unique in that MiStent has maintained numerically lower point estimates versus Xience for any revascularization, target vessel revascularization (TVR), and target vessel failure (TVF). DESSOLVE III was not powered to show statistical significance between MiStent and Xience.
DESSOLVE III 24-Month Endpoint |
MiStent |
Xience |
Clinically-Driven Target Lesion Revascularization (CD-TLR) |
4.6% |
5.4% |
Definite Stent Thrombosis |
0.6% |
1.0% |
Any revascularization |
12.5% |
15.5% |
Target Vessel Revascularization (TVR) |
6.9% |
8.5% |
Target Vessel Failure (TVF) |
9.7% |
10.8% |